Implementation of tripartite estimands using adherence causal estimators under the causal inference framework

Intercurrent events (ICEs) and missing values are inevitable in clinical trials of any size and duration, making it difficult to assess the treatment effect for all patients in randomized clinical trials. Defining the appropriate estimand that is relevant to the clinical research question is the first step in analyzing data. The tripartite estimands, which evaluate the treatment differences in the proportion of patients with ICEs due to adverse events, the proportion of patients with ICEs due to lack of efficacy, and the primary efficacy outcome for those who can adhere to study treatment under the causal inference framework, are of interest to many stakeholders in understanding the totality of treatment effects. In this manuscript, we discuss the details of how to estimate tripartite estimands based on a causal inference framework and how to interpret tripartite estimates through a phase 3 clinical study evaluating a basal insulin treatment for patients with type 1 diabetes.

[1]  ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials , 2020 .

[2]  Haoda Fu,et al.  A General Framework for Treatment Effect Estimators Considering Patient Adherence , 2020 .

[3]  B Ratitch,et al.  Recent Developments in the Prevention and Treatment of Missing Data , 2014, Therapeutic innovation & regulatory science.

[4]  D. Rubin,et al.  Principal Stratification in Causal Inference , 2002, Biometrics.

[5]  Donald B Rubin,et al.  Principal Stratification for Causal Inference With Extended Partial Compliance , 2008 .

[6]  Zhi Geng,et al.  Identifiability and Estimation of Causal Effects by Principal Stratification With Outcomes Truncated by Death , 2011 .

[7]  J. Tukey The Future of Data Analysis , 1962 .

[8]  Donald B. Rubin,et al.  Estimation of Causal Effects via Principal Stratification When Some Outcomes are Truncated by “Death” , 2003 .

[9]  Avi Feller,et al.  Principal Score Methods: Assumptions, Extensions, and Practical Considerations , 2017 .

[10]  Y. Fong,et al.  Transformation Model Choice in Nonlinear Regression Analysis of Fluorescence-Based Serial Dilution Assays , 2016, Statistics in biopharmaceutical research.

[11]  P. Gilbert,et al.  Sensitivity Analyses Comparing Time‐to‐Event Outcomes Only Existing in a Subset Selected Postrandomization and Relaxing Monotonicity , 2011, Biometrics.

[12]  Norbert Benda,et al.  Choosing Appropriate Estimands in Clinical Trials , 2015, Therapeutic innovation & regulatory science.

[13]  Max Welling,et al.  Causal Effect Inference with Deep Latent-Variable Models , 2017, NIPS 2017.

[14]  Tyler J VanderWeele,et al.  Principal Stratification -- Uses and Limitations , 2011, The international journal of biostatistics.

[15]  Heinz Schmidli,et al.  Bayesian inference for a principal stratum estimand to assess the treatment effect in a subgroup characterized by postrandomization event occurrence , 2019, Statistics in medicine.

[16]  Bohdana Ratitch,et al.  Causal Inference and Estimands in Clinical Trials , 2020 .

[17]  Thomas Permutt,et al.  A taxonomy of estimands for regulatory clinical trials with discontinuations , 2016, Statistics in medicine.

[18]  Björn Bornkamp,et al.  Estimating the Treatment Effect in a Subgroup Defined by an Early Post-Baseline Biomarker Measurement in Randomized Clinical Trials With Time-To-Event Endpoint , 2018, Statistics in Biopharmaceutical Research.

[19]  Kosuke Imai,et al.  Sharp bounds on the causal effects in randomized experiments with "truncation-by-death" , 2008 .

[20]  F. Travert,et al.  Randomized, double‐blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3 , 2016, Diabetes, obesity & metabolism.

[21]  S. Ruberg,et al.  Estimands in clinical trials – broadening the perspective , 2017, Statistics in medicine.

[22]  Tyler J VanderWeele,et al.  A simple method for principal strata effects when the outcome has been truncated due to death. , 2011, American journal of epidemiology.

[23]  Y. Lou,et al.  Estimation of causal effects in clinical endpoint bioequivalence studies in the presence of intercurrent events: noncompliance and missing data , 2018, Journal of biopharmaceutical statistics.

[24]  D. Pauler,et al.  An Estimator for Treatment Comparisons among Survivors in Randomized Trials , 2005, Biometrics.

[25]  임재영,et al.  BMI(Body Mass Index)가 소득에 미치는 영향 , 2012 .

[26]  Baldur P Magnusson,et al.  Bayesian inference for a principal stratum estimand to assess the treatment effect in a subgroup characterized by post-randomization events , 2018, 1809.03741.

[27]  T. Permutt Effects in Adherent Subjects , 2018, Statistics in Biopharmaceutical Research.